Tony de Fougerolles
A step behind its major exosome challenger, Evox scores $95M round for final leg of race to the clinic
After years of academic and early-stage biotech development, exosomes finally entered the clinic last year, when Codiak launched their Phase I/II trial in advanced solid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
